BlueCrest Capital Management’s Gilead Sciences GILD Stock Holding History

BlueCrest Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,553	Closed	-$1.5M	–	187
2025 Q2	$1.5M	Buy	+13,553	New	+$1.44M	0.06%	78
2019 Q2	–	Sell	-10,200	Closed	-$663K	–	675
2019 Q1	$663K	Buy	+10,200	New	+$678K	0.03%	390
2018 Q4	–	Sell	-3,403	Closed	-$263K	–	1070
2018 Q3	$263K	Buy	+3,403	New	+$257K	0.01%	1106
2017 Q1	–	Sell	-4,499	Closed	-$322K	–	825
2016 Q4	$322K	Buy	+4,499	New	+$334K	0.02%	534
2016 Q3	–	Sell	-27,289	Closed	-$2.28M	–	835
2016 Q2	$2.28M	Buy	27,289 +12,747	+88%	+$1.13M	0.09%	217
2016 Q1	$1.34M	Buy	+14,542	New	+$1.31M	0.08%	314
2015 Q3	–	Sell	-2,948	Closed	-$345K	–	925
2015 Q2	$345K	Buy	+2,948	New	+$322K	0.01%	687
2014 Q4	–	Sell	-4,866	Closed	-$518K	–	597
2014 Q3	$518K	Buy	+4,866	New	+$476K	0.02%	411

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlueCrest Capital Management's GILD Position: Q3 2025 in Review

BlueCrest Capital Management sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 13,553 shares — an estimated $1.5M sold.

BlueCrest Capital Management first reported a position in GILD in Q3 2014 and held it in 8 quarters. The position peaked at $2.28M in Q2 2016. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

BlueCrest Capital Management reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
BlueCrest Capital Management sold 13,553 Gilead Sciences shares in Q3 2025, an estimated $1.5M.
BlueCrest Capital Management first reported a position in Gilead Sciences in Q3 2014 and held it in 8 quarters.
BlueCrest Capital Management's Gilead Sciences position peaked at $2.28M in Q2 2016.
2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on BlueCrest Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.